MEET OUR TEAM
Anticancer Bioscience is led by an experienced management team and advised by a Scientific Advisory Board with deep expertise in oncology, translational research, and drug development.
As well as access to the scientific expertise of the J. Michael Bishop Institute of Cancer Research, we are advised by leading scientists and clinicians in oncology.
Our commercial expertise is strengthened through the experience of our board
ACB MANAGEMENT TEAM
Dr. Dun Yang
Founder
Executive Chair
Chief Scientific Strategy Officer
PhD, Columbia University
Postdoc, University of California, San Francisco, mentored by Nobel Laureate Dr. J. Michael Bishop
Dr. Xudong Lu
Chief Executive Officer
PhD, Shanghai University of Finance and Economics
Over 20 years of experience in global capital markets and IPO execution
Dr. Hong Liu
Executive Vice President
Chief Medical Officer
PhD, University of California, Berkley
Postdoc, University of California, San Francisco, mentored by Nobel Laureate Dr. J. Michael Bishop
Dr. Jing Zhang
Co-founder
Senior Vice President, Clinical Development
PhD, University of Nottingham, UK.
Postdoc, University of St Andrews, UK
SCIENTIFIC ADVISORY BOARD
Dr. J. Michael Bishop
Chancellor Emeritus, University of California, San Francisco
Nobel Laureate in Physiology or Medicine (1989)
Dr. Robert Lloyd
Fellow of the Royal Society (UK)
Former Director, Institute of Genetics, University of Nottingham.
Synthetic Lethality Screening Specialist
Dr. Dana Aftab
Executive Vice President of R & D
Chief Scientist Officer, Exelixis
Dr. Kevan Shokat
Pinoneer of RASG12C Inhibitor,
Professor and Chair,
Department of Cellular and Molecular Pharmacology in UCSF
Dr. Dean Felsher
Director of Translational Research and Applied Medicine,
Department of Medicine,
Stanford University School of Medicine.
Dr. Scott Kogan
Director of Hematopathology, University of California, San Francisco
Dr. Frank Buchholz
Professor of Medical Systems Biology
Dean of Research, Faculty of Medicine Carl Gustav Carus, TU Dresden